Growth Factor Receptor Fusions Predict Therapeutic Sensitivity

Dysregulated growth factor pathways promote tumor growth in many cancers, but receptor-targeting strategies frequently offer limited benefit despite activation by receptor overexpression or amplification. In contrast, tumors harboring growth factor receptor fusions display exquisite dependence on receptor activity, providing predictive markers for patient response to inform precise oncology treatment. Clin Cancer Res; 21(14); 3105–7. ©2015 AACR. See related article by Di Stefano et al., p. 3307

[1]  S. Rosenfeld,et al.  Phase II trial of dovitinib in recurrent glioblastoma. , 2015 .

[2]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[3]  Daniel J. Brat,et al.  GE-41COMPREHENSIVE AND INTEGRATIVE GENOMIC CHARACTERIZATION OF DIFFUSE LOWER GRADE GLIOMAS , 2014 .

[4]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[5]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Th. Boveri.  Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris , 2008, Journal of Cell Science.

[7]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[8]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[9]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[10]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[11]  Katrina H. Smith,et al.  Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas , 2014, Journal of Neuro-Oncology.

[12]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[13]  H. Harris.  Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. Preface. , 2008, Journal of cell science.

[14]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .